Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · IEX Real-Time Price · USD
4.90
-0.43 (-8.07%)
At close: Dec 29, 2023, 4:00 PM
4.91
+0.01 (0.20%)
After-hours: Dec 29, 2023, 7:33 PM EST
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $179.69M in the twelve months ending September 30, 2023, with 6.93% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $37.92M, a -20.72% decrease year-over-year. In the year 2022, Adaptive Biotechnologies had annual revenue of $185.31M with 20.06% growth.
Revenue (ttm)
$179.69M
Revenue Growth
+6.93%
P/S Ratio
3.95
Revenue / Employee
$227,456
Employees
790
Market Cap
709.39M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 185.31M | 30.96M | 20.06% |
| Dec 31, 2021 | 154.34M | 55.96M | 56.88% |
| Dec 31, 2020 | 98.38M | 13.31M | 15.65% |
| Dec 31, 2019 | 85.07M | 29.41M | 52.83% |
| Dec 31, 2018 | 55.66M | 17.22M | 44.77% |
| Dec 31, 2017 | 38.45M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zymeworks | 461.58M |
| Valneva SE | 237.46M |
| Travere Therapeutics | 209.65M |
| BioLife Solutions | 154.80M |
| OmniAb | 64.69M |
| PureTech Health | 15.62M |
| Fusion Pharmaceuticals | 2.21M |
ADPT News
- 4 days ago - Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 22 days ago - Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting - GlobeNewsWire
- 26 days ago - Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting - GlobeNewsWire
- 7 weeks ago - Adaptive Biotech hires Goldman Sachs to explore ‘strategic alternatives' for key business lines - GeekWire
- 7 weeks ago - Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene's Lymphoid Malignancy Pipeline - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023 - GlobeNewsWire
- 3 months ago - Adaptive Announces Launch of Epic Integration for clonoSEQ® - GlobeNewsWire